ST. PETERSBURG, Fla. and RICHMOND, Va. -- It's hard to imagine a baseball game without peanuts, but in a new collaboration between Minor League Baseball® (MiLB™) and AUVI-Q® (epinephrine injection, USP), fans that suffer from peanut allergies can enjoy America's national pastime with less concern.
The two groups today announced a multi-year agreement, making AUVI-Q the "Official Epinephrine Auto-Injector (EAI) of Minor League Baseball," where a number of MiLB teams across the country will host "Peanut-Free Game Days" this season and next season. AUVI-Q is an FDA-approved prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. AUVI-Q is the first and only EAI with an auto-retractable needle and includes innovative features such as voice instructions. AUVI-Q is not a substitute for emergency medical treatment.
As one of the most common food allergies, peanut sensitivity can lead to reactions ranging from mild irritation to anaphylactic shock, with peanut allergies becoming more prevalent in children. To make baseball games safer to sufferers of peanut allergies, the peanut free-games at MiLB ballparks will feature no in-park sales of peanuts or products containing peanut ingredients. The games throughout the partnership will also include informational displays and in-park messaging.
"With peanut allergies on the rise, AUVI-Q will support our overarching commitment to our fans," said David Wright, Chief Marketing & Commercial Officer for Minor League Baseball. "We hope that all families, regardless of existing allergies, can experience a Minor League Baseball game to its fullest during designated peanut-free nights."
"We're proud to support MiLB to help provide a safer environment for those who suffer from severe peanut allergies to enjoy one of our nation's favorite pastimes," said Dr. Eric Edwards, a life-threatening allergy sufferer and co-inventor of AUVI-Q. "AUVI-Q is committed to providing information and resources to help educate the public about life-threatening allergies and encourage a community of inclusion and acceptance."
The first peanut-free Minor League Baseball game sponsored by AUVI-Q is scheduled for Sunday, Aug. 6, at Smith's Ballpark, home of the Salt Lake Bees and at First Data Field, home of the St. Lucie Mets. All participating teams will announce their peanut-free game dates on their official websites. AUVI-Q, manufactured by kaléo, is available by prescription nationwide. To learn more about AUVI-Q, please visit www.auvi-q.com.
About Minor League Baseball
Minor League Baseball, headquartered in St. Petersburg, Florida, is the governing body for all professional baseball teams in the United States, Canada, and the Dominican Republic that are affiliated with Major League Baseball® clubs through their farm systems. Fans are coming out in unprecedented numbers to this one-of-a-kind experience that can only be found at Minor League Baseball ballparks. In 2016, Minor League Baseball attracted 41.3 million fans to its ballparks to see the future stars of the sport hone their skills. From the electricity in the stands to the excitement on the field, Minor League Baseball has provided affordable family-friendly entertainment to people of all ages since its founding in 1901. For more information, visit www.MiLB.com.
Follow Minor League Baseball on Facebook, Instagram and Twitter.
About kaléo (kuh-LAY-oh)
Kaléo is a pharmaceutical company dedicated to building innovative solutions for serious and life-threatening medical conditions. Our mission is to provide innovative solutions that empower patients to confidently take control of their medical conditions. We believe patients and caregivers are the experts on how their medical condition impacts their lives and are an integral part of our product development process. Kaléo is a privately-held company headquartered in Richmond, Virginia. For more information, visit www.kaleopharma.com.
AUVI-Q® (epinephrine injection, USP) Auto-injector is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or who have a history of serious allergic reactions. AUVI-Q contains epinephrine, a well-established, first-line treatment for severe, life-threatening allergic reactions that occur as a result of exposure to allergens including food such as peanuts, tree nuts, fish, shellfish, dairy, eggs, soy and wheat; insect stings or bites; latex and medication, among other allergens and causes.
AUVI-Q is the only compact epinephrine auto-injector with a voice instruction system that helps guide patients and caregivers step-by-step through the injection process, and a needle that automatically retracts following administration. In anaphylaxis emergencies, it is often individuals without medical training who need to step in and deliver potentially life-saving epinephrine. AUVI-Q was designed through careful analysis of the situations where epinephrine auto-injectors are used and with significant input from the allergy community that relies on it incorporating Human Factors Engineering (HFE). HFE is about designing products or systems that are easy to operate and, most importantly, support correct use, with the goal to remove the potential for error.
For more information, visit www.auvi-q.com.
AUVI-Q (epinephrine injection, USP) is a prescription medicine used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions.
Important Safety Information
AUVI-Q is for immediate self (or caregiver) administration and does not take the place of emergency medical care. Seek immediate medical treatment after use. Each AUVI-Q contains a single dose of epinephrine. AUVI-Q should only be injected into your outer thigh, through clothing if necessary. If you inject a young child with AUVI-Q, hold their leg firmly in place before and during the injection to prevent injuries. Do not inject into veins, buttocks, fingers, toes, hands, or feet. If you accidentally inject AUVI-Q into any other part of your body, seek immediate medical treatment.
Rarely, patients who use AUVI-Q may develop infections at the injection site within a few days of an injection. Some of these infections can be serious. Call your healthcare provider right away if you have any of the following symptoms at an injection site: redness that does not go away, swelling, tenderness, or the area feels warm to the touch.
If you have certain medical conditions, or take certain medicines, your condition may get worse or you may have more or longer lasting side effects when you use AUVI-Q. Be sure to tell your healthcare provider about all the medicines you take, especially medicines for asthma. Also tell your healthcare provider about all of your medical conditions, especially if you have asthma, a history of depression, thyroid problems, Parkinson's disease, diabetes, heart problems or high blood pressure, have any other medical conditions, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.
Common side effects include fast, irregular or 'pounding' heartbeat, sweating, shakiness, headache, paleness, feelings of over excitement, nervousness, or anxiety, weakness, dizziness, nausea and vomiting, or breathing problems. These side effects usually go away quickly, especially if you rest. Tell your healthcare provider if you have any side effect that bothers you or that does not go away.
Please click here to see the full Prescribing Information and the Patient Information at www.auvi-q.com.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.